Magnetic nanoparticles in theranostics of malignant melanoma

被引:10
作者
Shevtsov, Maxim [1 ,2 ,3 ]
Kaesler, Susanne [4 ]
Posch, Christian [4 ]
Multhoff, Gabriele [1 ,5 ]
Biedermann, Tilo [4 ]
机构
[1] Tech Univ Munich TUM, Klinikum Rechts Isar, Sch Med, Cent Inst Translat Canc Res TranslaTUM,Radiat Imm, Einstein Str 25, D-81675 Munich, Germany
[2] Far Eastern Fed Univ, Lab Biomed Cell Technol, Vladivostok 690091, Russia
[3] Almazov Natl Med Res Ctr, Personalized Med Ctr, 2 Akkuratova Str, St Petersburg 197341, Russia
[4] Tech Univ Munich TUM, Sch Med, Dept Dermatol & Allergol, Klinikum Rechts Isar, Biedersteinerstr 29, D-80802 Munich, Germany
[5] Tech Univ Munich TUM, Sch Med, Dept Radiat Oncol, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany
关键词
Melanoma; Magnetic nanoparticles; SPIONs; Theranostics; IRON-OXIDE NANOPARTICLES; LONG-TERM SURVIVAL; METASTATIC MELANOMA; CUTANEOUS MELANOMA; CANCER-CELLS; CLINICAL-APPLICATIONS; GOLD NANOPARTICLES; POOLED ANALYSIS; NAB-PACLITAXEL; TUMOR-CELLS;
D O I
10.1186/s13550-021-00868-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Malignant melanoma is an aggressive tumor with a tendency to metastasize early and with an increasing incidence worldwide. Although in early stage, melanoma is well treatable by excision, the chances of cure and thus the survival rate decrease dramatically after metastatic spread. Conventional treatment options for advanced disease include surgical resection of metastases, chemotherapy, radiation, targeted therapy and immunotherapy. Today, targeted kinase inhibitors and immune checkpoint blockers have for the most part replaced less effective chemotherapies. Magnetic nanoparticles as novel agents for theranostic purposes have great potential in the treatment of metastatic melanoma. In the present review, we provide a brief overview of treatment options for malignant melanoma with different magnetic nanocarriers for theranostics. We also discuss current efforts of designing magnetic particles for combined, multimodal therapies (e.g., chemotherapy, immunotherapy) for malignant melanoma.
引用
收藏
页数:15
相关论文
共 175 条
  • [1] Polymer coated gold-ferric oxide superparamagnetic nanoparticles for theranostic applications
    Abedin, Muhammad Raisul
    Umapathi, Siddesh
    Mahendrakar, Harika
    Laemthong, Tunyaboon
    Coleman, Holly
    Muchangi, Denise
    Santra, Santimukul
    Nath, Manashi
    Barua, Sutapa
    [J]. JOURNAL OF NANOBIOTECHNOLOGY, 2018, 16
  • [2] Basic Science Research in Thermal Ablation
    Ahmed, Muneeb
    Goldberg, S. Nahum
    [J]. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 20 (02) : 237 - +
  • [3] Metal-Free Organo-Theranostic Nanosystem with High Nitroxide Stability and Loading for Image-Guided Targeted Tumor Therapy
    Akakuru, Ozioma U.
    Xu, Chen
    Liu, Chuang
    Li, Zihou
    Xing, Jie
    Pan, Chunshu
    Li, Yanying
    Nosike, Elvis, I
    Zhang, Zhoujing
    Iqbal, Zubair M.
    Zheng, Jianjun
    Wu, Aiguo
    [J]. ACS NANO, 2021, 15 (02) : 3079 - 3097
  • [4] Genomic Classification of Cutaneous Melanoma
    Akbani, Rehan
    Akdemir, Kadir C.
    Aksoy, B. Arman
    Albert, Monique
    Ally, Adrian
    Amin, Samirkumar B.
    Arachchi, Harindra
    Arora, Arshi
    Auman, J. Todd
    Ayala, Brenda
    Baboud, Julien
    Balasundaram, Miruna
    Balu, Saianand
    Barnabas, Nandita
    Bartlett, John
    Bartlett, Pam
    Bastian, Boris C.
    Baylin, Stephen B.
    Behera, Madhusmita
    Belyaev, Dmitry
    Benz, Christopher
    Bernard, Brady
    Beroukhim, Rameen
    Bir, Natalie
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Boland, Genevieve M.
    Bono, Riccardo
    Bootwalla, Moiz S.
    Bosenberg, Marcus
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brockway-Lunardi, Laura
    Brooks, Denise
    Brzezinski, Jakub
    Bshara, Wiam
    Buda, Elizabeth
    Burns, William R.
    Butterfield, Yaron S. N.
    Button, Michael
    Calderone, Tiffany
    Cappellini, Giancarlo Antonini
    Carter, Candace
    Carter, Scott L.
    Cherney, Lynn
    Cherniack, Andrew D.
    Chevalier, Aaron
    Chin, Lynda
    [J]. CELL, 2015, 161 (07) : 1681 - 1696
  • [5] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [6] Recent advances in uveal melanoma treatment
    Alvarez-Rodriguez, Beatriz
    Latorre, Alfonso
    Posch, Christian
    Somoza, Alvaro
    [J]. MEDICINAL RESEARCH REVIEWS, 2017, 37 (06) : 1350 - 1372
  • [7] Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015
    Arnold, M.
    Holterhues, C.
    Hollestein, L. M.
    Coebergh, J. W. W.
    Nijsten, T.
    Pukkala, E.
    Holleczek, B.
    Tryggvadottir, L.
    Comber, H.
    Bento, M. J.
    Diba, Ch. S.
    Micallef, R.
    Primic-Zakelj, M.
    Izarzugaza, M. I.
    Perucha, J.
    Marcos-Gragera, R.
    Galceran, J.
    Ardanaz, E.
    Schaffar, R.
    Pring, A.
    de Vries, E.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (09) : 1170 - 1178
  • [8] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
    Ascierto, Paolo A.
    McArthur, Grant A.
    Dreno, Brigitte
    Atkinson, Victoria
    Liszkay, Gabrielle
    Di Giacomo, Anna Maria
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Yan, Yibing
    Wongchenko, Matthew
    Chang, Ilsung
    Hsu, Jessie J.
    Koralek, Daniel O.
    Rooney, Isabelle
    Ribas, Antoni
    Larkin, James
    [J]. LANCET ONCOLOGY, 2016, 17 (09) : 1248 - 1260
  • [9] The role of BRAF V600 mutation in melanoma
    Ascierto, Paolo A.
    Kirkwood, John M.
    Grob, Jean-Jacques
    Simeone, Ester
    Grimaldi, Antonio M.
    Maio, Michele
    Palmieri, Giuseppe
    Testori, Alessandro
    Marincola, Francesco M.
    Mozzillo, Nicola
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [10] Avgoustakis Konstantinos, 2004, Current Drug Delivery, V1, P321, DOI 10.2174/1567201043334605